SILO vs TNON
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.
TNON exhibits critical financial fragility with a Piotroski F-Score of 1/9, signaling severe weakness in profitability and operational efficiency. While the company shows impressive top-line momentum with 92.3% YoY revenue growth and maintains a low debt profile, these are overshadowed by a catastrophic -193.52% operating margin and a -228.06% ROE. The long-term price performance is devastating, with a near 100% loss over 5 years, suggesting a failed historical value proposition. Despite optimistic analyst price targets, the deterministic health metrics indicate a high risk of continued equity erosion.
Compare Another Pair
Related Comparisons
SILO vs TNON: Head-to-Head Comparison
This page compares Silo Pharma, Inc. (SILO) and Tenon Medical, Inc. (TNON) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.